• Home
• SCOUT DS®
• Technology
• News & Events
• Company

 

 
• Diabetes: A Global Threat
  
   
• Health Implications of Diabetes
  
   
• Need for Improved Screening
  
   
• A New Approach to Screening
  
   
• No Blood, Fasting, or Waiting
  
   
• Clinical Performance
  
   
• Interpretation of Results
  
   
• SCOUT DS - Video
  

The VeraLight SCOUT DS®

Diabetes is a global epidemic that has enormous health, social, and economic implications. Because the urgency of early diabetes detection is critical in helping stem this epidemic, VeraLight has developed the SCOUT DS system. The SCOUT DS system is the first noninvasive diabetes screening system designed to provide a highly sensitive and convenient method for screening for prediabetes and type 2 diabetes based on the presence of diabetes-related biomarkers found in skin. Unlike current screening methods, a SCOUT DS test requires no blood draw, no fasting, and no waiting for a lab result.

SCOUT DS has received approval from Health Canada for commercial distribution and it has been granted a CE Mark in the European Union.

US Caution: Federal law restricts the SCOUT DS system to investigational use only. Commercial distribution has not been granted by the US FDA. See SCOUT DS Operation Manual for descriptions of all relevant Warnings, Cautions, Contraindications, & Safety Information.